In patients with prostate cancer that has spread to bone, treatment with zoledronic acid reduces the risk of skeletal events, according to a report published in the October 2nd issue of the Journal of the National Cancer Institute.
In a recent phase III trial, zoledronic acid, a new bisphosphonate produced by Swiss drug company Novartis under the trade name Zometa (Zomera in Israel), showed promise in preventing skeletal complications in patients with multiple myeloma or breast cancer.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!